OncoSec Medical (ONCS) Stock Price
OncoSec Medical Price
Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.
OncoSec Medical stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of OncoSec Medical over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how OncoSec Medical stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing OncoSec Medical's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | OncoSec Medical Price |
|---|
OncoSec Medical Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
OncoSec Medical Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | 8.00 | 8.00 | 9.00 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 12.50 |
| -1.00 | -5.00 | -7.00 | -11.00 | -21.00 | -26.00 | -21.00 | -36.00 | -30.00 | -43.00 | -48.00 | -37.00 | -37.00 | -35.00 | -34.00 | -34.00 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -437.50 | -425.00 | -377.78 |
| -3.00 | -2.00 | -7.00 | -12.00 | -21.00 | -26.00 | -21.00 | -39.00 | -30.00 | -42.00 | -45.00 | -34.00 | -95.00 | -19.00 | -22.00 | -27.00 |
| – | -33.33 | 250.00 | 71.43 | 75.00 | 23.81 | -19.23 | 85.71 | -23.08 | 40.00 | 7.14 | -24.44 | – | – | 15.79 | 22.73 |
| 39.37 | 39.37 | 39.37 | 39.37 | 39.37 | 39.37 | 39.37 | 39.37 | 39.37 | 39.37 | 39.37 | 39.37 | 39.37 | 39.37 | 39.37 | 39.37 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales OncoSec Medical generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue OncoSec Medical retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare OncoSec Medical's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares OncoSec Medical has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against OncoSec Medical's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
OncoSec Medical stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
OncoSec Medical Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
OncoSec Medical business model & stock analysis
OncoSec Medical SWOT Analysis
Strengths
1. Strong Intellectual Property (IP) Portfolio: OncoSec Medical Inc possesses a robust IP portfolio that includes patents and trademarks, providing a competitive advantage in the field of immunotherapy.
2. Innovative Technology: The company's proprietary technology, called ImmunoPulse®, enables the delivery of DNA-based immunotherapies directly into tumors, offering a potentially effective and safer treatment option.
3. Promising Clinical Pipeline: OncoSec has a diverse and promising clinical pipeline, with multiple ongoing trials in various stages for different cancer indications, indicating potential future revenue streams.
Weaknesses
1. Limited Market Presence: OncoSec Medical Inc faces strong competition from well-established pharmaceutical and biotechnology companies in the rapidly evolving immunotherapy market, making it challenging to gain market share.
2. High Research and Development (R&D) Expenditure: The company's focus on innovation and clinical development necessitates significant R&D spending, which may strain finances in the absence of substantial revenues.
3. Regulatory Risks: As an emerging biotech company, OncoSec is subject to regulatory scrutiny and faces risks associated with obtaining necessary approvals for its products, which could delay commercialization timelines.
Opportunities
1. Growing Demand for Immunotherapies: Increasing prevalence of cancer and the need for more effective treatment options present significant market opportunities, especially in the field of immunotherapy, where OncoSec operates.
2. Collaborations and Partnerships: OncoSec can explore collaborations and partnerships with larger pharmaceutical companies to expand its market reach, leverage existing distribution channels, and gain access to additional resources.
3. Expansion into International Markets: As the company continues to demonstrate the efficacy of its products, expanding into international markets can provide additional revenue streams and tap into regions with substantial unmet medical needs.
Threats
1. Competitive Landscape: The immunotherapy market is highly competitive, with established players and other emerging biotechnology companies constantly introducing new and advanced therapies, posing a threat to OncoSec's market position.
2. Stringent Regulations: Changing regulations and compliance requirements in the healthcare and biotechnology sectors can significantly impact OncoSec's operations, increasing costs and causing delays.
3. Technological Advancements: Rapid advancements in technology may render OncoSec's current technology obsolete or less effective, necessitating continuous innovation and potential investments to stay competitive.
OncoSec Medical Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
OncoSec Medical Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
OncoSec Medical historical P/E ratio, EBIT multiple, and P/S ratio
OncoSec Medical annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
OncoSec Medical shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
OncoSec Medical stock splits
Current OncoSec Medical forecasts and price targets in August 2026
Analyst Price Targets 2026OncoSec Medical Analyst Rating Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| 11/14/2022 | Downgrade | BuyNeutral | |
| 3/16/2022 | Maintained | Buy | |
| 3/8/2021 | Maintained | Buy | |
| 11/25/2020 | Maintained | Buy | |
| 11/25/2020 | Maintained | Buy | |
| 7/27/2020 | Maintained | Buy | |
| 11/7/2018 | Downgrade | BuyNeutral | |
| 4/23/2018 | Maintained | Buy | |
| 3/9/2016 | Maintained | Buy |
OncoSec Medical Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 12/14/2022 | -3.81USD | - | 0.00USD | - | 2023 Q1 |
| 11/22/2022 | -0.24USD | - | 0.00USD | - | 2022 Q4 |
| 6/14/2022 | -4.04USD | - | 0.00USD | - | 2022 Q3 |
| 3/15/2022 | -5.95USD | - | 0.00USD | - | 2022 Q2 |
| 12/15/2021 | -0.38USD | - | 0.00USD | - | 2022 Q1 |
| 10/29/2021 | -0.29USD | - | 0.00USD | - | 2021 Q4 |
| 6/11/2021 | -0.31USD | - | 0.00USD | - | 2021 Q3 |
| 3/15/2021 | -0.37USD | - | 0.00USD | - | 2021 Q2 |
| 12/11/2020 | -0.37USD | - | 0.00USD | - | 2021 Q1 |
| 10/28/2020 | -0.39USD | - | 0.00USD | - | 2020 Q4 |
OncoSec Medical shareholder structure
| % | Name |
|---|---|
1.93964% | |
0.38793% | |
0.08497% | |
0.06398% | |
0.06142% | |
0.05284% |
OncoSec Medical Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
44.10% | SEC ↗ | |
44.10% | SEC ↗ | |
9.90% | SEC ↗ | |
9.90% | SEC ↗ | |
8.80% | SEC ↗ | |
8.60% | SEC ↗ | |
8.60% | SEC ↗ | |
8.50% | SEC ↗ | |
7.50% | SEC ↗ | |
7.50% | SEC ↗ |
OncoSec Medical Supply Chain
OncoSec Medical Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.26 | 0.88 | 0.91 | ||
| 2 | 0.62 | 0.88 | 0.52 | ||
| 3 | 0.39 | 0.72 | 0.39 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.30 | -0.48 | — | ||
| 2 | -0.49 | -0.40 | -0.50 | ||
| 3 | 0.13 | 0.39 | -0.25 | ||
| 4 | 0.11 | -0.05 | 0.01 |
Frequently asked questions about OncoSec Medical
The business model of OncoSec Medical Inc focuses on developing innovative immunotherapy treatments for cancer patients. By leveraging its proprietary technology, OncoSec aims to empower the body's immune system to effectively target and destroy tumor cells. The company's comprehensive approach includes utilizing electroporation to enhance the delivery of DNA-based immunotherapies directly into the tumor. By doing so, OncoSec seeks to provide patients with potential solutions that are both safe and effective in combating various types of cancer. Through ongoing research and development, OncoSec Medical Inc strives to revolutionize cancer treatment and improve patient outcomes.
OncoSec Medical Inc is primarily active in the biotechnology and healthcare industries.
The main competitors of OncoSec Medical Inc in the market include companies like Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis AG, Genentech, Inc., and Amgen Inc. These pharmaceutical giants operate in the same healthcare sector, specializing in oncology and immunotherapy. While OncoSec Medical Inc focuses on developing innovative and effective cancer treatments, it faces competition from these established players who also strive to provide cutting-edge advancements in the field.
OncoSec Medical Inc. is a biotechnology company focused on developing innovative immunotherapies to combat cancer. Established in 2011, the company has grown rapidly due to its commitment to pioneering research and development. OncoSec's expertise lies in its proprietary technology platform, ImmunoPulse®, which harnesses the power of electroporation to enhance the delivery of DNA-based immunotherapies directly into the tumor. By leveraging this cutting-edge approach, OncoSec aims to revolutionize cancer treatment and improve patient outcomes. With a strong emphasis on clinical trials and strategic partnerships, OncoSec continues to make significant strides in the field of oncology.
OncoSec Medical Inc has achieved several significant milestones in the field of cancer immunotherapy. The company successfully completed the Phase II OMS Study, demonstrating positive clinical results in patients with metastatic melanoma. They also received FDA Breakthrough Therapy Designation for their lead product candidate, TAVO, which facilitates the local delivery of DNA-based immunotherapies. OncoSec Medical Inc further expanded its pipeline through strategic collaborations with Merck and Roswell Park Comprehensive Cancer Center. The company's dedication to advancing innovative therapies and improving patient outcomes has positioned OncoSec Medical Inc as a key player in the immunotherapy industry.
OncoSec Medical Inc is primarily present in the United States.
OncoSec Medical Inc represents values of innovation, commitment, and patient-focused care. The company philosophy revolves around advancing novel oncology treatments through its proprietary ImmunoPulse® platform technology. With a strong focus on delivering effective and safe therapies, OncoSec Medical Inc prioritizes patient well-being and aims to improve cancer treatment outcomes. Through strategic collaborations and a dedicated research and development approach, the company strives to redefine the way cancer is treated, offering hope to patients worldwide. OncoSec Medical Inc's commitment to transforming cancer therapy reinforces its position as a leading player in the oncology sector.
6 analysts currently rate the OncoSec Medical stock: 0 recommend buying, 3 holding and 3 selling.
The OncoSec Medical share (ONCS) is listed on 3 stock exchanges, including: NASDAQ (ONCS), Frankfurt (ONM2.F), München (ONM2.MU).
OncoSec Medical Inc is a leading company in the field of immuno-oncology therapy. Based in San Diego, California, the company aims to develop a novel class of cancer treatments that specifically activate the patient's own immune system, potentially leading to healing effects. OncoSec Medical's core business involves the research, development, and commercialization of immune-dominant therapy approaches based on the innovation of electroporation technology. This technology uses electrical pulses to enhance the delivery of therapeutic agents into tumor cells, resulting in more targeted and effective therapeutic outcomes. The flagship product of OncoSec Medical is the ImmunoPulse System, a groundbreaking therapy that synergistically combines electroporation and immunity to generate coordinated anti-tumoral immune responses. The system provides a fast, highly effective, and safe treatment option that has a positive impact on the survival of patients with advanced skin cancer. ImmunoPulse is capable of treating both primary and metastatic tumors and has the potential to be used in many other cancer types. In addition to ImmunoPulse, OncoSec Medical also offers other innovative therapy approaches such as the DNA plasmid vector system. This system aims to inhibit the rheostat function of tumor cells in the growth factor signaling pathway, thereby inhibiting tumor growth. OncoSec Medical also has a pipeline of products, including OMS-776, an agonist of Toll-like receptors that is capable of enhancing the immune response to the tumor microenvironment, and OMS-905, an immunosuppressive drug that improves T-cell regulation in cancer patients. OncoSec Medical is an innovative company that collaborates closely with leading scientists and research partners to develop the next generation of cancer treatments. The company is committed to revolutionizing the way cancer is treated and improving the lives of patients worldwide. With its unique approach and strong pipeline of products, OncoSec Medical is well positioned to meet the evolving needs of patients and providers in the field of cancer treatment. In summary, OncoSec Medical's business model consists of a combination of research, development, and commercialization of immuno-oncology therapies based on innovative electroporation technology. The company offers a wide range of products, including the ImmunoPulse system, DNA plasmid vectors, and drug candidates such as OMS-776 and OMS-905. With its strong pipeline of products and vision to revolutionize cancer treatment, OncoSec Medical is an exciting and promising company that plays a prominent role in cancer research and treatment.
The revenue cannot currently be calculated for OncoSec Medical.
The profit cannot currently be calculated for OncoSec Medical.
The P/E ratio cannot be calculated for OncoSec Medical at the moment.
The P/S cannot be calculated for OncoSec Medical currently.
The Eulerpool Quality Score for OncoSec Medical is 2/10.
The ISIN of OncoSec Medical is US68234L3069. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of OncoSec Medical is A2PKW3. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of OncoSec Medical is ONCS. The ticker symbol is used to trade OncoSec Medical shares on the stock exchange.
OncoSec Medical is assigned to the 'Health' sector.
The dividends of OncoSec Medical are distributed in USD.
OncoSec Medical stock
OncoSec Medical Peer Group
OncoSec Medical Ticker
All fundamentals and in-depth analysis of OncoSec Medical
Our stock analysis for OncoSec Medical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OncoSec Medical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.